Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.

Two groups of patients with disseminated breast carcinomas who had failed radiotherapy, chemotherapy, and hormonotherapy were treated with natural interferon alpha (nIFN-alpha) alone or in combination with nIFN-gamma delivered in cycles of 10-12 intralesional (i.l.) injections to recurrent and metastatic lesions. In group, I, 16 skin lesions in 12 patients received nIFN-alpha alone resulting in 7 complete regressions verified histologically (CR), 7 partial regressions (PR), and no regressions (NR) in 2. Group II included 4 patients in whom 7 cutaneous recurrences were treated with nIFN-alpha/nIFN-gamma (5 CR, 2 PR), 2 were injected with nIFN-alpha alone (1 CR, 1 PR), and 1 received nIFN-gamma alone (PR). Two additional patients in group II were given i.l. injections of nIFN-alpha/nIFN-gamma to lymph node metastases (1 CR, 1 PR). Clinical toxicity was experienced by 5 of 12 patients in group I and by all the patients in group II and was controlled in most instances by antipyretics. Systemic antitumor effects were not appreciable clinically. Nevertheless, noninjected lesions exposed only to systemic levels of IFNs, when studied immunohistochemically, displayed an immunological response similar to that of IFN-injected lesions, although less intense. Therefore, IFNs can be useful in controlling locoregional recurrences of breast cancer even in patients who are not responding to other forms of therapy. Furthermore, in addition to the local antitumor actions, they appear to be capable of eliciting systemic immunological effects.

[1]  K. Cantell,et al.  Cellular Events Accompanying Regression of Skin Recurrences of Breast Carcinomas Treated with Intralesional Injections of Natural Interferons α and γ , 1992 .

[2]  S. Jacques,et al.  The systemic administration of gamma interferon inhibits collagen synthesis and acute inflammation in a murine skin wounding model. , 1989, The Journal of investigative dermatology.

[3]  K. Foon Biological response modifiers: the new immunotherapy. , 1989, Cancer research.

[4]  K. Cantell,et al.  Treatment of Human Breast Cancer Xenografts Using Natural Interferons-α and -γ Injected Singly or in Combination , 1988 .

[5]  K. Cantell,et al.  Effects of intralesional injections of interferons-alpha on xenografts of human mammary carcinoma cells (BT20 and MCF-7). , 1988, Journal of interferon research.

[6]  H. Deicher,et al.  Intralesional interferon‐alpha therapy in advanced malignant melanoma , 1988, Cancer.

[7]  J. Laszlo,et al.  Interferon therapy in cancer: from imaginon to interferon. , 1986, Cancer research.

[8]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Ceriani,et al.  Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule , 1983, Somatic cell genetics.

[10]  K. Cantell,et al.  Clinical and laboratory investigations on man: systemic administration of potent interferon to man. , 1973, Journal of the National Cancer Institute.

[11]  J. Willson,et al.  Synergistic Antiproliferative Effects of Human Recombinant «54-or ßser-Interferon with 7-lnterferon on Human Cell Lines of Various Histogenesis1 , 2006 .

[12]  E. Borden Effects of interferons in neoplastic diseases of man. , 1988, Pharmacology & therapeutics.

[13]  K. Cantell,et al.  Presence of Tumor Necrosis Factor and Lymphotoxin in Clinical Interferon Preparations Derived from Leukocytes , 1987 .

[14]  R. Rosso,et al.  Antitumoral activity of human fibroblast interferon administered intranodularly. , 1985, Oncology.

[15]  K. Cantell,et al.  Production of interferon in human leukocytes from normal donors with the use of Sendai virus. , 1981, Methods in enzymology.

[16]  G. Murphy Current report on the interferon program at Roswell Park Memorial Institute , 1981, Journal of surgical oncology.

[17]  K. Cantell,et al.  Partial purification of human leukocyte interferon on a large scale. , 1981, Methods in enzymology.